PORTO · PORTUGAL
Lung Cancer
Treatment
Controversies
About the Event
Treatment of Lung Cancer – Controversies is an annual workshop bringing together leading experts in thoracic oncology to debate the most pressing clinical questions of our time.
Through short lectures and pro–con debates, participants engage in structured discussions, draw conclusions, and vote on key controversies — fostering open dialogue between specialists from around the world.
The 2026 edition takes place on 6–7 November at the School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Portugal.
Scientific Programme
Day 1 — Friday, 6 November
08:15
› Registration Opening
08:45–09:00
› Welcome & Objectives
SESSION 1
09:00–13:00
Early Stages: Are We Over or Under-Treating?
Chairs: Delvys Rodriguez-Abreu & Christian Rolfo
› Perioperative vs neo-adjuvant IO
Speakers: Lizza Hendriks vs Alfredo Addeo
› Are we ready for targeted therapy in resected oncogene-driven NSCLC?
Speakers: Jessica Lin vs Rosario Garcia Campelo
10:45–11:15
› Coffee Break
› Should MRD guide adjuvant therapy in 2026?
Speaker: Christian Rolfo
› In multiple station N2, bulky N2 or T4 – Neoadjuvant pre-surgery or chemoradiation and IO?
Speakers: Cecilia Pompili vs Suresh Senan
13:00–14:00
› Lunch
SESSION 2
14:00–18:00
First-line Treatment for advanced NSCLC: what is the size?
Chairs: Stephen Liu & Jessica Lin
› PD-L1 ≥50%: IO alone vs chemo-IO or IO combinations.
Speakers: Stephen Liu vs Enriqueta Felip
› Sequencing vs combinations in oncogene-driven disease.
Speakers: Delvys Rodriguez-Abreu vs Jessica Lin
15:45–16:15
› Coffee Break
› What is the best duration of the IO therapy? Two years vs until disease progression.
Speakers: Benjamin Besse vs Joachim Aerts
› The value of new strategies (like ADCs or bispecific antibodies) vs (and) the need for new biomarkers.
Speaker: Jordi Remon
Day 2 — Saturday, 7 November
SESSION 3
09:00–13:00
mSCLC: Is This the Future?
Chairs: António Araújo & Luiz Paz-Ares
› Molecular subtypes and other biomarkers: ready for clinical use?
Speaker: Alvaro Quintanal-Villalonga
› Maintenance with PD-L1/PD-1 inhibitors or Lurbinectedin+Atezolizumab?
Speakers: Andrea Ardizzoni vs Martin Reck
10:45–11:15
› Coffee Break
› T-Cells Engager – some patients in some centers or most patients in most centers?
Speakers: Fiona Blackhall vs Luiz Paz-Ares
› After chemo-immunotherapy progression: should we move directly to T-cell engagers or still sequence conventional therapies?
Speakers: Benjamin Besse vs Stephen Liu
13:00–13:30
› Closing Session
› Take-home messages and consensus gaps
› Proposal for post-meeting position paper
Organizing Committee
António Araújo · Delvys Rodriguez-Abreu · Stephen Liu · Luiz Paz-Ares
Scientific Panel
Alfredo Addeo (1) · Alvaro Quintanal-Villalonga (2) · Andrea Ardizzoni (3) · António Araújo (4) · Benjamin Besse (5) · Cecilia Pompili (6) · Christian Rolfo (7) · Delvys Rodriguez-Abreu (8) · Enriqueta Felip (9) · Fiona Blackhall (10) · Joachim Aerts (11) · Jessica Lin (12) · Jordi Remon (13) · Lizza Hendriks (14) · Luiz Paz-Ares (15) · Martin Reck (16) · Rosario Garcia Campelo (17) · Stephen Liu (18) · Suresh Senan (19)
Venue
School of Medicine and Biomedical Sciences – ICBAS
University of Porto
Rua de Jorge de Viterbo Ferreira, 228
4050-313 Porto, Portugal
Registration
Payment Information
Bank transfer details will be provided upon registration confirmation.
Beneficiary: ONCOL MED SERVICOS SAUDE UNIPESSOAL, LDA
IBAN: PT50 0035 2085 0000 3942 0304 1
SWIFT: CGDIPTPL
After payment, a receipt will be issued and sent to your email by the secretariat.
Technical Secretary: Skyros Congressos, Lda
Lung Cancer Treatment Controversies 2026
06–07 November 2026 · ICBAS, University of Porto · Porto, Portugal
Technical Secretary: Skyros Congressos, Lda
© 2026 Treatment of Lung Cancer – Controversies.
All rights reserved.